Dimensional Fund Advisors LP Sells 144,340 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Dimensional Fund Advisors LP reduced its holdings in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 15.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,866 shares of the company's stock after selling 144,340 shares during the period. Dimensional Fund Advisors LP owned about 1.61% of Cryoport worth $5,465,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CYRX. Massachusetts Financial Services Co. MA lifted its position in shares of Cryoport by 2.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,035,586 shares of the company's stock worth $14,066,000 after purchasing an additional 52,103 shares in the last quarter. Federated Hermes Inc. purchased a new stake in Cryoport in the 2nd quarter worth approximately $774,000. NRI Wealth Management LC acquired a new stake in shares of Cryoport during the 2nd quarter valued at $132,000. Quest Partners LLC grew its holdings in shares of Cryoport by 1,083,000.0% during the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company's stock valued at $75,000 after acquiring an additional 10,830 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Cryoport by 3.4% in the second quarter. Rhumbline Advisers now owns 64,158 shares of the company's stock worth $443,000 after acquiring an additional 2,086 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ramkumar Mandalam sold 4,167 shares of the firm's stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.04, for a total value of $33,502.68. Following the sale, the director now directly owns 56,032 shares of the company's stock, valued at approximately $450,497.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 7,167 shares of company stock valued at $60,363 in the last quarter. Insiders own 10.10% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on CYRX shares. Needham & Company LLC reduced their price objective on Cryoport from $18.00 to $11.00 and set a "buy" rating for the company in a research report on Wednesday, August 7th. B. Riley upgraded Cryoport from a "neutral" rating to a "buy" rating and reduced their price target for the company from $19.00 to $15.00 in a report on Wednesday, July 31st. UBS Group dropped their price objective on Cryoport from $17.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. Finally, Jefferies Financial Group lowered shares of Cryoport from a "buy" rating to a "hold" rating and cut their price objective for the company from $20.00 to $8.00 in a research report on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Cryoport currently has an average rating of "Hold" and a consensus price target of $11.60.

Cryoport Stock Performance

Shares of CYRX stock traded down $0.17 during trading on Wednesday, reaching $6.78. The company had a trading volume of 660,698 shares, compared to its average volume of 589,958. The firm's 50 day simple moving average is $8.31 and its two-hundred day simple moving average is $10.84. Cryoport, Inc. has a one year low of $5.32 and a one year high of $20.10. The company has a debt-to-equity ratio of 0.97, a current ratio of 8.38 and a quick ratio of 7.99. The company has a market capitalization of $333.96 million, a PE ratio of -2.74 and a beta of 1.60.

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($0.37) by ($1.25). Cryoport had a negative net margin of 76.48% and a negative return on equity of 15.55%. The company had revenue of $57.60 million for the quarter, compared to analyst estimates of $57.65 million. During the same quarter last year, the business earned ($0.42) EPS. The company's revenue for the quarter was up 1.0% on a year-over-year basis. Sell-side analysts forecast that Cryoport, Inc. will post -1.63 earnings per share for the current year.

Cryoport announced that its Board of Directors has initiated a stock repurchase program on Tuesday, August 6th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 49.1% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.